Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy

Transplant International

Volumn 22, Issue 10, 2009, Pages 961-969

  Nishida, Hayato ^a   Ishida, Hideki ^a   Tanaka, Toshiaki ^b   Amano, Hiroyuki ^a   Omoto, Kazuya ^a   Shirakawa, Hiroki ^a   Shimizu, Tomokazu ^a   Iida, Shoichi ^a   Toki, Daisuke ^a   Yamaguchi, Yutaka ^c   Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CMV seroconversion; Cytomegalovirus; Induction therapy; Renal transplantation; Rituximab

Indexed keywords

ACICLOVIR; BASILIXIMAB; CYCLOSPORIN A; GANCICLOVIR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; SEROCONVERSION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SPLENECTOMY; TRANSPLANTATION CONDITIONING;

EID: 69949165414     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00903.x     Document Type: Article

References (33)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 83 : 435.
2. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody in patients with recurrent B-cell lymphoma. Blood 1994 84 : 2457.
3. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody in patients with refractory immune thrombocytopenia. Semin Oncol 2000 27 : 99.
4. Tsokos GC. B cell, be gone - B-cell depletion in the treatment of rheumatoid arthritis. New England J Med 2004 350 : 2546.
5. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-trasplantation lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 2006 107 : 3053.
6. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2004 5 : 145.
7. Saito K, Nakagawa Y, Suwa M, et al. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 2006 13 : 111.
8. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1.Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004 77 : 542.
9. Garrett Jr. HE, Duvall-Seaman D, Helsley B, et al. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant 2005 24 : 1337.
10. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgikin's lymphoma (NHL) cell lines. Blood 1996 88 : 637.
11. Mitsuhata N, Fujita R, Ito S, et al. Delayed-onset neutropenia in a patient receiving rituximab treatment for refractory kidney transplantation. Transplantation 2005 80 : 1355.
12. Nishio M, Endo T, Fujimoto K, et al. Persistent panhypogammagloburinemia with selected loss of momory B-cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Hematol 2005 75 : 527.
13. Ljungman P, Griffiths P, Paya C. Difinitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002 34 : 1094.
14. Alexandre GP, De Bruyere M, Squifflet JP, et al. Human ABO-incompatible living donor renal homografts. Neth J Med 1985 28 : 231.
15. Lee MY, Chiou TJ, Hsiao LT, et al. Rituximab therapy increases post-transplant cytomegalovirus in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 2008 87 : 285.
16. Askoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infection in lymphoma patients. Leuk Lymphoma 2007 48 : 1307.
17. Yoshikawa A, Sakamoto K, Ogawa M, et al. ABO Barrier: The use of rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc 2005 37 : 1718.
18. Kumar D, Gourishankar S, Mueller T, et al. Pneumocytis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis 2009 11 : 167.
19. Kolstad A, Holte H, Foss A, et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007 92 : 139.
20. Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABO incompatible living donor kidney transplantation in Japan. Am J Transplant 2004 4 : 1089.
21. Schröder C, Azimzadeh AM, Wu G, et al. Anti-CD20 treatment depletes B-cell in blood and lymphatic tissure of cynomolgus monkeys. Transpl Immunol 2003 12 : 19.
22. Agarwal A, Vieira CA, Book BK, et al. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004 4 : 1357.
23. Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004 13 : 55.
24. Ramos EJ, Pollinger HS, Stegall JM, et al. The effect of desensitization protocol on human splenic B-cell populations in vivo. Am J Transplant 2007 7 : 402.
25. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001 345 : 1000.
26. Bearden CM, Agarwal A, Pescovitz MD, et al. Rituximab inhibits the in vivo primary and secondary response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005 5 : 50.
27. van der Kolk LE, Barrs JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002 100 : 2257.
28. Gonzalez-Stawinski GV, Yu PB, Love SD, et al. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 2001 98 : 175.
29. Hamaguchi Y, Uchida J, Cain DW, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 2005 174 : 4389.
30. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989 261 : 3607.
31. Cainelli F, Vento S. Infections and solid organ transplant rejections: a cause-and-effect relationship? Lancet Infect Dis 2002 2 : 539.
32. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006 6 : 2134.
33. O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008 111 : 1816.